PharVision Advisers’s Macerich MAC Stock Holding History

PharVision Advisers’s Portfolio MAC Stock Details MAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,442	Closed	-$179K	–	368
2025 Q1	$179K	Buy	+10,442	New	+$200K	0.25%	211

Other funds holding MAC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Smead Capital Management Phoenix, Arizona $4.6B AUM 27.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PharVision Advisers's MAC Position: Q2 2025 in Review

PharVision Advisers sold out of Macerich (MAC) in Q2 2025, closing a stake of 10,442 shares — an estimated $179K sold.

PharVision Advisers first reported a position in MAC in Q1 2025 and held it in 1 quarter. The position peaked at $179K in Q1 2025. 289 funds tracked by Wall St. Rank hold MAC as of Q2 2025.

PharVision Advisers reported no remaining Macerich position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 10,442 Macerich shares in Q2 2025, an estimated $179K.
PharVision Advisers first reported a position in Macerich in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Macerich position peaked at $179K in Q1 2025.
289 funds tracked by Wall St. Rank held Macerich as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.